A Phase 1 Study of DZD8586 in People With B-Cell Non-Hodgkin Lymphoma

Full Title

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Purpose

Researchers want to find the best dose of DZD8586 to give to people with B-cell non-Hodgkin lymphoma (B-NHL). The people in this study have B-NHL that keeps growing even with treatment. Examples of these lymphomas include:

• Diffuse large B-cell lymphoma (DLBCL)
• Mantle cell lymphoma (MCL)
• Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
• Follicular lymphoma (FL)
• Marginal zone lymphoma (MZL)
• Central nervous system lymphoma (CNSL)

DZD8586 is a type of drug called a BTK inhibitor. BTK inhibitors block the action of enzymes that may be too active or found at high levels in some types of cancer cells. By blocking these enzymes, DZD8586 may help slow or stop cancer growth. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have DLBCL, MCL, CLL/SLL, FL, MZL, or CNSL that has come back or keeps growing after treatment.
• Have recovered from the serious side effects of anti-cancer therapy before taking DZD8586.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please contact Dr. Lindsey Roeker’s office at 646-608-4115.